Kevin J. Carroll

On the use and utility of the Weibull model in the analysis of survival data

Kevin J. Carroll · Controlled Clinical Trials · 2003 · 286 citations

Public Health, Biostatistics, Actuarial Science +11

Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

Laurence Collette, Tomasz Burzykowski, Kevin J. Carroll et al. · Journal of Clinical Oncology · 2005 · 110 citations

Medicine, Biostatistics, Oncology +17

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Angus Dalgleish, Justin Stebbing, Douglas JA Adamson et al. · British Journal of Cancer · 2016 · 75 citations · Full text

Medicine, Oncology, Pharmacology +13

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

Vincent Brandenburg, Smeeta Sinha, José‐Vicente Torregrosa et al. · Journal of Nephrology · 2019 · 49 citations

Nursing, Pharmacology, Pharmacotherapy +10

The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis

Smeeta Sinha, Lisa J. Gould, Sagar U. Nigwekar et al. · Clinical Kidney Journal · 2021 · 37 citations · Full text

Medicine, Nephrology, Pharmacotherapy +10